May 18, 2006
LICR Research Pivotal in Approval of Cervical Cancer Vaccine
(New York, Brazil) — A US Food and Drug Administration (FDA) Advisory Panel today voted unanimously that Merck has demonstrated the safety and efficacy of the cervical cancer vaccine, GardasilTM. The panel’s findings, which are typically followed by FDA approval, was predicated on immunogenicity data conducted largely by a team led by Dr. Luisa L. Villa, Acting Director of LICR’s Sao Paulo Branch. Dr. Villa was also the lead author of the first study reporting Gardasil’s efficacy in 2005.
LICR press release from April 6, 2005: Vaccine Reduces Human Papillomavirus Infection and Disease